Evidence map›Paper›PMID 35836307›Full record

ArticleNeuropathology and applied neurobiology2022

The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases.

Mélanie Pagès, Marie-Anne Debily, Frédéric Fina, David T W Jones, Raphael Saffroy, David Castel, Thomas Blauwblomme, Alice Métais, Marie Bourgeois, Emmanuèle Lechapt-Zalcman and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Neuropathology and applied neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 4 countries.

Mélanie PagèsGHU-Paris - Sainte-Anne Hospital, Department of Neuropathology, Paris University, Paris, France.
Marie-Anne DebilyMolecular Predictors and New Targets in Oncology, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Frédéric FinaAPHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
David T W JonesPediatric Glioma Research, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Raphael SaffroyOncogenetics Department, Assistance Publique-Hôpitaux de Paris, Paul Brousse Hospital, Université Paris-Saclay, Villejuif, France.
David CastelMolecular Predictors and New Targets in Oncology, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Thomas BlauwblommePediatric Neurosurgery Department, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Alice MétaisGHU-Paris - Sainte-Anne Hospital, Department of Neuropathology, Paris University, Paris, France.
Marie BourgeoisPediatric Neurosurgery Department, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Emmanuèle Lechapt-ZalcmanGHU-Paris - Sainte-Anne Hospital, Department of Neuropathology, Paris University, Paris, France.
Arnault Tauziède-EspariatGHU-Paris - Sainte-Anne Hospital, Department of Neuropathology, Paris University, Paris, France.
Felipe AndreiuoloDepartment of Neuropathology, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil.
Fabrice ChrétienGHU-Paris - Sainte-Anne Hospital, Department of Neuropathology, Paris University, Paris, France.
Jacques GrillMolecular Predictors and New Targets in Oncology, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Nathalie BoddaertPediatric Radiology Department, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
Dominique Figarella-BrangerAPHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
Rameen BeroukhimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pascale VarletGHU-Paris - Sainte-Anne Hospital, Department of Neuropathology, Paris University, Paris, France.
Centre Hospitalier Sainte-Anne · FRUniversité Paris-Saclay · FRHôpital Necker-Enfants Malades · FRInserm · FRDana-Farber Cancer Institute · USD’Or Institute for Research and Education · BRHeidelberg University · DEHôpital de la Timone · FRInstitut de Neurophysiopathologie · FRUniversité Paris Cité · FR

Funding

Genetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9M
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine GliomasR01CA219943 · NCI · BROAD INSTITUTE, INC. · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.5M
NCI NIH HHS R01 CA188228NCI NIH HHS R01 CA219943
6 · The paper itself

Abstract

aimsDysembryoplastic neuroepithelial tumour (DNT) is a glioneuronal tumour that is challenging to diagnose, with a wide spectrum of histological features. Three histopathological patterns have been described: specific DNTs (both the simple form and the complex form) comprising the specific glioneuronal element, and also the non-specific/diffuse form which lacks it, and has unclear phenotype-genotype correlations with numerous differential diagnoses.

methodsWe used targeted methods (immunohistochemistry, fluorescence in situ hybridisation and targeted sequencing) and large-scale genomic methodologies including DNA methylation profiling to perform an integrative analysis to better characterise a large retrospective cohort of 82 DNTs, enriched for tumours that showed progression on imaging.

resultsWe confirmed that specific DNTs are characterised by a single driver event with a high frequency of FGFR1 variants. However, a subset of DNA methylation-confirmed DNTs harbour alternative genomic alterations to FGFR1 duplication/mutation. We also demonstrated that a subset of DNTs sharing the same FGFR1 alterations can show in situ progression. In contrast to the specific forms, "non-specific/diffuse DNTs" corresponded to a heterogeneous molecular group encompassing diverse, newly-described, molecularly distinct entities.

conclusionsSpecific DNT is a homogeneous group of tumours sharing characteristics of paediatric low-grade gliomas: a quiet genome with a recurrent genomic alteration in the RAS-MAPK signalling pathway, a distinct DNA methylation profile and a good prognosis but showing progression in some cases. The "non-specific/diffuse DNTs" subgroup encompasses various recently described histomolecular entities, such as PLNTY and diffuse astrocytoma, MYB or MYBL1 altered.

Indexed as

Brain NeoplasmsGliomaNeoplasms, NeuroepithelialGenomicsHumansRetrospective StudiesDNA methylation profilingdysembryoplastic neuroepithelial tumoursFGFR1glioneuronal tumoursmolecular pathologypaediatric low-grade gliomas

Identifiers

PMID35836307
PMCPMC9542977
OpenAlexW4285594505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.